(4-((3-methoxybenzyl)oxy)phenyl)methanamine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-((3-methoxybenzyl)oxy)phenyl)methanamine
• 英文别名: 1-{4-[(3-Methoxybenzyl)oxy]phenyl}methanamine；[4-[(3-methoxyphenyl)methoxy]phenyl]methanamine
• 化学式: C₁₅H₁₇NO₂
• mdl: MFCD08699702
• 分子量: 243.305
• InChiKey: BVTIJAGTLLXDSI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (4-((3-methoxybenzyl)oxy)phenyl)methanamine 、 6-氯-3-甲酰基-1H-吲哚-2-羧酸乙酯 在 lithium hydroxide 作用下， 以 甲醇 、 乙醇 、 水 为溶剂， 反应 72.0h， 生成 3-(2-(tert-butylamino)-1-(N-(4-((3-methoxybenzyl)oxy)benzyl)formamido)-2-oxoethyl)-6-chloro-1H-indole-2-carboxylic acid
  参考文献：
  名称：

  Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction

  摘要：

  Intrinsically disordered proteins are an emerging class of proteins without a folded structure and currently disorder-based drug targeting remains a challenge. p53 is the principal regulator of cell division and growth whereas MDM2 consists its main negative regulator. The MDM2-p53 recognition is a dynamic and multistage process that amongst other, employs the dissociation of a transient alpha-helical N-terminal "lid" segment of MDM2 from the proximity of the p53-complementary interface. Several small molecule inhibitors have been reported to inhibit the formation of the p53-MDM2 complex with the vast majority mimicking the p53 residues Phe19, Trp23 and Leu26. Recently, we have described the transit from the 3-point to 4-point pharmacophore model stabilizing this intrinsically disordered N-terminus by increasing the binding affinity by a factor of 3. Therefore, we performed a thorough SAR analysis, including chiral separation of key compound which was evaluated by FP and 2D NMR. Finally, p53-specific anti-cancer activity towards p53-wild-type cancer cells was observed for several representative compounds. (C) 2019 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2019.111588
• 作为产物：
  描述：

  在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.5h， 生成 (4-((3-methoxybenzyl)oxy)phenyl)methanamine
  参考文献：
  名称：

  Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction

  摘要：

  Intrinsically disordered proteins are an emerging class of proteins without a folded structure and currently disorder-based drug targeting remains a challenge. p53 is the principal regulator of cell division and growth whereas MDM2 consists its main negative regulator. The MDM2-p53 recognition is a dynamic and multistage process that amongst other, employs the dissociation of a transient alpha-helical N-terminal "lid" segment of MDM2 from the proximity of the p53-complementary interface. Several small molecule inhibitors have been reported to inhibit the formation of the p53-MDM2 complex with the vast majority mimicking the p53 residues Phe19, Trp23 and Leu26. Recently, we have described the transit from the 3-point to 4-point pharmacophore model stabilizing this intrinsically disordered N-terminus by increasing the binding affinity by a factor of 3. Therefore, we performed a thorough SAR analysis, including chiral separation of key compound which was evaluated by FP and 2D NMR. Finally, p53-specific anti-cancer activity towards p53-wild-type cancer cells was observed for several representative compounds. (C) 2019 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2019.111588

文献信息

• Novel antifungal agent containing heterocyclic compound
  申请人：Nakamoto Kazutaka

  公开号：US20070105943A1

  公开（公告）日：2007-05-10

  The present invention provides an antifungal agent represented by the formula: [wherein A 1 represents a 3-pyridyl group which may have a substituent, a quinolyl group which may have a substituent, or the like; X 1 represents a group represented by the formula —NH—C(═O)—, a group represented by the formula —C(═O)—NH—, or the like; E represents a furyl group, a thienyl group, a pyrrolyl group, a phenyl group, a pyridyl group, a tetrazolyl group, a thiazolyl group or a pyrazolyl group; with the proviso that A 1 may have 1 to 3 substituents, and E has one or two substituents].

  本发明提供了一种抗真菌剂，其表示为以下式子： [其中A1表示一个3-吡啶基团，可能具有取代基，喹啉基团，可能具有取代基或类似物；X1表示由公式—NH—C（═O）—，由公式—C（═O）—NH—或类似物表示的基团；E表示呋喃基团，噻吩基团，吡咯基团，苯基团，吡啶基团，四唑基团，噻唑基团或吡唑基团；但A1可能具有1到3个取代基，E具有一个或两个取代基。]
• Novel Antimalarial Agent Containing Heterocyclic Compound
  申请人：Nakamoto Kazutaka

  公开号：US20090227799A1

  公开（公告）日：2009-09-10

  Disclosed is an antimalarial agent containing a compound represented by the formula: [wherein A 1 represents a 3-pyridyl group that may have a substituent, a 6-quinolyl group that may have a substituent, or the like; X 1 represents a group represented by the formula —C(═O)—NH— or the like; E represents a furyl group, a thienyl group or a phenyl group; with the proviso that A 1 may have one to three substituents, and E has one of two substituents] or a salt thereof or hydrates thereof.

  揭示了一种抗疟疾剂，其包含由下式表示的化合物： [其中A1表示一个3-吡啶基团，可以有取代基，一个6-喹啉基团，可以有取代基或类似物；X1表示一个由公式-C（═O）-NH-或类似物表示的基团；E表示一个呋喃基团，噻吩基团或苯基团；但前提是A1可以有1到3个取代基，E有两个取代基之一]或其盐或水合物。
• NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND
  申请人：NAKAMOTO Kazutaka

  公开号：US20110195999A1

  公开（公告）日：2011-08-11

  The present invention provides an antifungal agent represented by the formula: wherein A 1 represents a 3-pyridyl group which may have a substituent, a quinolyl group which may have a substituent, or the like; X 1 represents a group represented by the formula —NH—C(═O)—, a group represented by the formula —C(═O)—NH—, or the like; E represents a furyl group, a thienyl group, a pyrrolyl group, a phenyl group, a pyridyl group, a tetrazolyl group, a thiazolyl group or a pyrazolyl group; with the proviso that A 1 may have 1 to 3 substituents, and E has one or two substituents.

  本发明提供一种抗真菌剂，其化学式如下： 其中，A1代表3-吡啶基，可以有取代基，喹啉基，也可以有取代基等；X1代表由公式—NH—C（═O）—，由公式—C（═O）—NH—等表示的基团；E代表呋喃基，噻吩基，吡咯基，苯基，吡啶基，四唑基，噻唑基或吡唑基；但要求A1可能有1到3个取代基，E有1或2个取代基。
• NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND
  申请人：Eisai Co., Ltd.

  公开号：EP1669348A1

  公开（公告）日：2006-06-14

  The present invention provides an antifungal agent represented by the formula: [wherein A1 represents a 3-pyridyl group which may have a substituent, a quinolyl group which may have a substituent, or the like; X1 represents a group represented by the formula -NH-C(=O)-, a group represented by the formula -C(=O)-NH-, or the like; E represents a furyl group, a thienyl group, a pyrrolyl group, a phenyl group, a pyridyl group, a tetrazolyl group, a thiazolyl group or a pyrazolyl group; with the proviso that A1 may have 1 to 3 substituents, and E has one or two substituents].

  本发明提供了一种由式表示的抗真菌剂： [其中A1代表可具有取代基的3-吡啶基、可具有取代基的喹啉基或类似基团；X1代表由式-NH-C(＝O)-代表的基团、由式-C(＝O)-NH-代表的基团或类似基团；E 代表呋喃基、噻吩基、吡咯基、苯基、吡啶基、四唑基、噻唑基或吡唑基；但 A1 可具有 1 至 3 个取代基，E 具有 1 或 2 个取代基]。
• NOVEL ANTIMALARIA AGENT CONTAINING HETEROCYCLIC COMPOUND
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP1782811A1

  公开（公告）日：2007-05-09

  Disclosed is an antimalarial agent containing a compound represented by the formula: [wherein A1 represents a 3-pyridyl group that may have a substituent, a 6-quinolyl group that may have a substituent, or the like; X1 represents a group represented by the formula -C(=O)-NH- or the like; E represents a furyl group, a thienyl group or a phenyl group; with the proviso that A1 may have one to three substituents, and E has one of two substituents] or a salt thereof or hydrates thereof.

  本发明公开了一种抗疟药剂，其中含有一种由式......表示的化合物： [其中 A1 代表可具有取代基的 3-吡啶基、可具有取代基的 6-喹啉基或类似基团；X1 代表由式-C(＝O)-NH-或类似基团表示的基团；E 代表呋喃基、噻吩基或苯基； 但 A1 可具有一至三个取代基，E 具有两个取代基中的一个]或其盐或其水合物。